Abel Hall LLC Raises Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

Abel Hall LLC boosted its stake in Insmed Incorporated (NASDAQ:INSM) by 4.7% during the fourth quarter, HoldingsChannel reports. The firm owned 3,333 shares of the biopharmaceutical company’s stock after buying an additional 151 shares during the period. Abel Hall LLC’s holdings in Insmed were worth $230,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. CIBC Asset Management Inc boosted its position in Insmed by 3.5% during the 3rd quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 149 shares during the period. Commerce Bank lifted its holdings in Insmed by 2.4% in the 3rd quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 163 shares during the period. Nisa Investment Advisors LLC grew its position in shares of Insmed by 5.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 183 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 224 shares during the period. Finally, Atomi Financial Group Inc. raised its holdings in shares of Insmed by 1.4% during the third quarter. Atomi Financial Group Inc. now owns 23,248 shares of the biopharmaceutical company’s stock valued at $1,697,000 after acquiring an additional 314 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. Truist Financial reissued a “buy” rating and issued a $105.00 price target (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Bank of America lifted their price objective on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Finally, JPMorgan Chase & Co. increased their target price on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research report on Friday, November 22nd. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $83.67.

Insider Activity at Insmed

In related news, CFO Sara Bonstein sold 3,470 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.70, for a total value of $227,979.00. Following the sale, the chief financial officer now owns 114,736 shares in the company, valued at approximately $7,538,155.20. The trade was a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO William Lewis sold 31,805 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $70.18, for a total transaction of $2,232,074.90. Following the transaction, the chief executive officer now owns 379,534 shares of the company’s stock, valued at $26,635,696.12. This trade represents a 7.73 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 104,740 shares of company stock worth $7,161,294. Corporate insiders own 4.60% of the company’s stock.

Insmed Trading Down 0.6 %

Shares of INSM stock opened at $78.00 on Thursday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $80.53. The firm’s 50 day moving average is $72.28 and its 200 day moving average is $72.97.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. During the same period last year, the business earned ($1.10) EPS. The company’s revenue for the quarter was up 18.1% compared to the same quarter last year. On average, equities analysts expect that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.